Valacyclovir for Genital Herpes: Evidence, Suppression, and Safety

Valacyclovir is an oral antiviral that the body converts into acyclovir. On its own it is an L-valyl ester of acyclovir, a chemical handle attached to the active drug that helps it cross the gut wall. Once absorbed, first-pass metabolism in the intestine and liver strips that handle off and releases acyclovir into the blood (FDA label).

The point of this design is absorption. Acyclovir taken as a pill is absorbed poorly, so much of a dose passes through unused. Valacyclovir is absorbed well and then turns into acyclovir, which raises the amount of active drug the body actually gets. In studies the absolute bioavailability of acyclovir from a valacyclovir dose was about 54%, several times higher than acyclovir taken directly (FDA label). The practical result is fewer pills per day for the same effect.

Valacyclovir treats HSV-1 and HSV-2, which cause oral and genital herpes, and it also treats shingles caused by the chickenpox virus. This page focuses on genital herpes.

Valacyclovir stops the herpes virus from copying its own DNA. After the body converts it to acyclovir, a viral enzyme called thymidine kinase adds the first phosphate group to the drug. This step happens efficiently only inside infected cells, because the virus supplies that enzyme, so the drug concentrates where the infection is and largely spares healthy cells.

The cell then adds two more phosphate groups, producing acyclovir triphosphate. This active form blocks the viral DNA polymerase, the machine the virus uses to copy its genetic material, and gets built into the growing DNA chain in a way that halts it. With its copying machinery jammed, the virus cannot multiply. This selectivity is why valacyclovir works against the virus with few effects on the rest of the body. For a closer look at the prodrug difference, see valacyclovir compared with acyclovir.

The FDA first approved valacyclovir, under the brand Valtrex, in 1995 (FDA label). Approved uses include treatment of genital herpes, both the first episode and recurrent outbreaks, daily suppression of recurrent genital herpes, reduction of transmission to a partner, cold sores, and shingles. Generic valacyclovir has been available for years and is inexpensive.

The transmission claim is notable: valacyclovir is the antiviral with an FDA-approved indication for lowering the risk of passing genital HSV-2 to a susceptible partner, based on the trial described below.

Daily valacyclovir lowers the risk of passing genital herpes to a partner. The key trial followed 1,484 couples in which one partner had symptomatic HSV-2 and the other did not, and randomly assigned the infected partner to take 500 mg of valacyclovir once daily or a placebo for eight months (Corey 2004).

The results were clear. Overall, HSV-2 was caught by 1.9% of partners whose source took valacyclovir, against 3.6% in the placebo group, a hazard ratio of 0.52 that works out to about a 48% lower risk of acquisition. Looking only at infections that caused symptoms, valacyclovir cut the risk by about 75% (hazard ratio 0.25). The drug also sharply lowered viral shedding, with HSV DNA found on 2.9% of days for the valacyclovir group against 10.8% for placebo (Corey 2004).

These numbers describe added protection, not a guarantee. Both groups were counseled on safer sex and offered condoms, so valacyclovir reduces transmission on top of those measures rather than replacing them. The plain reading: daily use roughly halves a partner's overall risk and cuts symptomatic infections by about three-quarters. The full numbers are laid out in the herpes transmission risk figures.

Valacyclovir can be taken two ways, and they answer different goals. Daily suppressive therapy means taking the drug every day to hold the virus down. Episodic treatment means taking it only when an outbreak begins, to cut that episode short.

Suppressive therapy reduces how often outbreaks happen and how much the virus sheds between them, and it is the approach that lowers transmission. In a one-year randomized trial of 1,479 people, every daily valacyclovir dose was significantly better than placebo at preventing or delaying recurrences (Reitano 1998). For most people with fewer than 10 outbreaks a year, 500 mg once daily was enough; people with more frequent outbreaks did better on a higher or split dose (Reitano 1998, CDC 2021).

Episodic therapy uses a short, higher-dose course started at the first warning signs, the tingling or itching that often comes before sores. Catching it early shortens the outbreak. The CDC lists both approaches as standard, with specific regimens for the first episode, for recurrences, and for daily suppression (CDC 2021). Which to choose comes down to outbreak frequency, how much the outbreaks bother a person, and whether protecting a partner is a goal. That trade-off is worked through in daily suppression versus episodic treatment.

Resistance to valacyclovir is rare in people with normal immune systems. Because acyclovir depends on a viral enzyme for its first activation step, the virus can become resistant if that enzyme mutates, but this is uncommon in the general population. Surveys put resistance in immunocompetent people at well under 1% (Bacon 2003).

The picture is different for people who are immunocompromised, such as those with advanced HIV or recipients of transplants. In these groups resistant virus is more common and can cause outbreaks that do not respond to standard treatment, which is one reason their care is managed more closely (Bacon 2003). For the typical person with genital herpes and a working immune system, resistance is not a practical concern.

Most people tolerate valacyclovir well. The common side effects in trials were headache and nausea, and the safety profile across the dosing options was similar (Reitano 1998, FDA label). It is taken by many people for years as daily suppression without trouble.

The effects that need attention involve the kidneys. Acyclovir can crystallize in the kidney if a person is dehydrated or takes high doses, which can reduce kidney function; staying well hydrated lowers this risk, and doses are adjusted for people with existing kidney impairment (FDA label). At very high doses, mainly in immunocompromised patients, the label notes rare reports of a serious blood disorder called thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (FDA label). These are not expected at the doses used for genital herpes in healthy people.

People should not take valacyclovir if they have had an allergic reaction to it or to acyclovir. Anyone with reduced kidney function should make sure the prescriber knows, so the dose can be set correctly.